PepGen Faces Investor Suit Over Muscular Dystrophy Drug

By Sydney Price · June 11, 2025, 6:35 PM EDT

Clinical-stage biotech company PepGen Inc. has been hit with a proposed shareholder class action alleging it misled investors about the efficacy and commercial prospects of its muscular dystrophy drug, causing share...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Karam v. PepGen Inc. et al

Case Number

1:25-cv-03221

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

June 09, 2025